Monographie - Mitomycin

Utolsó frissítés :
19/11/2024

Mitomycin

Kémiai szerkezet

Kereskedelmi név

A kereskedelmi név meghatározó jelentőségű: a készítmények összetétele országonként, előállítóként eltérő lehet

Ametycine	Franciaország
Crisofimina	Argentína
Fatrix	Chile
Maximitom	Argentína
Maximiton	Ecuador
Minazol	Colombia
Mitameta	Olaszország
Mitem	Németország, Svájc
Mitocin	Brazília
Mitokebir	Argentína, Ecuador
Mitolem	Colombia, Venezuela
Mitomicina	Argentína, Chile, Ecuador, Mexikó, Olaszország, Peru, Portugália, Románia, Spanyolország
Mitomycin	Amerikai Egyesült Államok, Ausztria, Belgium, Dánia, Finnország, Görögország, Irán, Írország, Lengyelország, Magyarország, Malaysia, Nagy-Britannia, Németország, Norvégia, Olaszország, Svédország, Szlovénia, Törökország, új-Zéland
Mitomycine	Hollandia, Luxemburg
Mitotie	Argentína, Chile, Ecuador, Peru
Mitozytrex	Amerikai Egyesült Államok
Mixandex	Colombia, Mexikó
Mutamycin	Amerikai Egyesült Államok
Riptam	Colombia
Ronzine	Argentína, Peru
Urocin	Németország

Irodalom : Mitomycin

	Type	publikáció
3	Napló	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
81	Napló	Trissel LA, Martinez JF. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 672-678.
84	Napló	Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499.
99	Napló	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
169	Napló	Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363.
182	Napló	Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60.
244	Napló	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
249	Napló	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
307	Napló	Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799.
334	Napló	Trissel LA, Tramonte SM, Grilley BJ. Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 988-992.
335	Napló	Trissel LA, Bready BB, Kwan JW, Santiago NM. Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 402-406.
407	Napló	Quebberman EJ, Hoffman NE, Ausman RK, Hamid AAR. Stability of mitomycin admixtures. Am J Hosp Pharm 1985 ; 42: 1750-1754.
485	Napló	Dorr RT, Liddil JD. Stability of mitomycin C in different infusion fluids: compatibility with heparin and glucocorticosteroids. J Oncol Pharm Practice 1995 ; 1: 19-24.
648	Napló	Das Gupta V. Stability of mitomycin aqueous solution when stored in tuberculin syringes. Int J Pharm Compound 1997 ; 1: 282-283.
835	Napló	Edwards D, Selkirk AB, Taylor RB. Determination of the stability of mitomycin C by high performance liquid chromatography. Int J Pharm 1979 ; 4: 21-26.
905	Napló	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.
1026	Napló	Mayron D, Gennaro AR. Stability and compatibility of topotecan hydrochloride with selected drugs. Am J Health-Syst Pharm 1999 ; 56: 875-881.
1178	Napló	Benvenuto JA, Anderson RW, Kerkof K, Smith RG, Loo TL. Stability and compatibility of antitumor agents in glass and plastic containers. Am J Hosp Pharm 1981 ; 38: 1914-1918.
1239	Napló	Stolk LML, Fruijtier A, Umans. Stability after freezing and thawing of solutions of mitomycin C in plastic minibags for intravesical use. Pharm Weekbl [Sci] 1986 ; 8: 286-288.
1410	Napló	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1423	Napló	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1827	Napló	Beijnen JH, Van Gijn R, Underberg WJM. Chemical stability of the antitumor mitomycin C in solutions for intravesical instillation. J Parenter Sci Technol 1990 ; 44: 332-335.
2247	Napló	Chan P, Heatherly K, Kupiec T.C, Trissel L.A. Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2008 ; 12, 3: 276-278.
3128	Laboratórium	Mitomycine (Amétycine®) - Résumé Caractéristiques du Produit Prostrakan 2013
3575	Laboratórium	Mitomycine (Ametycine®) - Résumé des caractéristiques du produit Prostrakan 2013
3897	Napló	Briot T, Truffaut C, Le Quay L, Lebreton A, Lagarce F. Stability of Reconstituted and Diluted Mitomycin C Solutions in Polypropylene Syringes and Glass Vials. Pharmaceutical Technology in Hospital Pharmacy 2016 ;1,2:83-89
4154	Laboratórium	Bleomycin sulfate- Summary of Product Characteristics Accord Health Care 2018
4282	Napló	Myers A-L, Zhang Y-P, Kawedia J-D, Zhou X,. Sobocinski S-M, Metcalfe M-J, Kramer M-A, Dinney C.P.N, Kamat A-M. Solubilization and Stability of Mitomycin C Solutions Prepared for Intravesical Administration. Drugs R D 2017
4367	Napló	Kinast R.M, Akula K.K, DeBarber A.E, Barker G.T, Gardiner S.K, Whitson E, Mansberger S.L. The Degradation of Mitomycin C Under Various Storage Methods. J Glaucoma 2016 ; 25, 6: 477-481.
4471	Laboratórium	Amétycine 10 mg poudre pour solution injectable - Résumé des caractéristiques du produit - Oct 10, 2019 Kyowa Kirin Pharma 2019
4526	Napló	Nisse, Y.E, Vigneron J, Zenier H, D'Huart E, Demoré B. Stability of mitomycin in polypropylene syringes for use in glaucoma surgery. EJOP 2021 4: 1.
4763	Napló	Almasi J, Erdnuss F, Thiesen J, Krämer I. Physicochemical stability of urea-containing Mitomycin C preparations in glass vials (1.0 mg/mL) and plastic syringes (2.0, 0.4, 0.2 mg/mL) Pharmaceutical Technology in Hospital Pharmacy 2023 ;8,1

Mentions Légales